It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

The lowest dose of Novo Nordisk's weight-loss drug, Wegovy, was listed as available, the U.S. health regulator's website ...

Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs ...

A new study found a link between NovoNordisk’s blockbuster drug Ozempic and a reduced risk of Alzheimer’s disease. 23andMe, ...

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according ...

The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years ...

After years of ongoing shortages due to their growing popularity, all doses of both Ozempic and Wegovy are now listed as ...

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned ...

Novo Nordisk just hit a technical red flag with a Death Cross, but its strong fundamentals suggest a potential rebound.

The Danish drugmaker Novo Nordisk contends that semaglutide, the active ingredient in Ozempic and Wegovy, is too complex for ...